leisure time -WSS

leisure time

author：explore 2025-09-30 00:46:04 - browse：295

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Sickle cell gene therapy cures need to be accessible in Africa

explore

knowledge

leisure time

WSS

Noem? Reynolds? A very early look at the Republican 'veepstakes'

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Churchill Downs extends trainer Bob Baffert's ban through 2024

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

What does generative AI mean for health care? We asked experts

Grail's uphill battle for Medicare to cover its cancer screening test

Bright Health sells Medicare Advantage business to Molina

Inflation cooled significantly in June, bringing price hikes close to normal levels

How to save PrEP access — and even expand it

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Heart attack and stroke risk calculators need revising

Britney Spears to release memoir, 'The Woman In Me,' later this year

Apple is now the first public company to be valued at $3 trillion

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

hotspot

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

US judge blocks portions of new Florida elections law

Chicago flooding is stark reminder of vulnerability of major cities during extreme weather

Elon Musk announces 'temporary limits' for reading Twitter posts

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

explore

knowledge

leisure time

hotspot